Press Release 2021 - Sami-Sabinsa Group | Formerly Known as Sami Labs Limited

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

Sami-Sabinsa Reaches Intellectual Property Milestone with over 300 Patents Granted

Sami-Sabinsa Cosmeceutical Ingredients COSMOS Approved: Cococin™, Saberry®, and Nigellin® Amber

Research Published on Sami-Sabinsa's Curcumin C3 Complex® / BioPerine® Combination as Adjuvant Therapy in COVID-19 Patients

Court Orders Prakruti to Pay over $1 Million in Fees and Costs to Sami-Sabinsa as a Sanction for Discovery Abuses in Litigation

Sami-Sabinsa Founder Dr. Muhammed Majeed Named Father of Indian Nutraceuticals Industry by ASSOCHAM

New Research Published on Sami-Sabinsa’s Curcumin C3 Reduct® Supports Efficacy as an Oral Care Ingredient

About

Certificates

Global Contacts List

Get in Touch